Skip to main content
Signal8

Rawcliffe Adrian

SEC insider (Form 3/4/5 filer). CIK 0001555851. Director at Wave Life Sciences, Inc. (WVE) and 1 other issuer. 12 reported Form 4/5 transactions since Sep 2024; latest on Oct 5, 2026. Located in CAMBRIDGE, MA.

Companies Rawcliffe Adrian has filed insider reports for

  • Wave Life Sciences, Inc. (WVE): Director
  • Adaptimmune Therapeutics PLC (ADAP): Director, Officer, Chief Executive Officer
Rawcliffe Adrian profile photo

Rawcliffe Adrian

CIK: 0001555851

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)7 (58.3%)

Position reduction

Option Exercises (M)1 (8.3%)

Derivative conversions

Awards (A)4 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

Wave Life Sciences, Inc. logo
WVE

Wave Life Sciences, Inc.

Director
Adaptimmune Therapeutics PLC logo
ADAP

Adaptimmune Therapeutics PLC

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

  • Wave Life Sciences, Inc. logo
    WVE

    Wave Life Sciences, Inc.

    Oct 5, 2026
    Award
    Direct
    10.7K shares-
  • Wave Life Sciences, Inc. logo
    WVE

    Wave Life Sciences, Inc.

    Aug 12, 2026
    Sale
    Direct
    12.7K shares at avg. $5.29$67K
  • Wave Life Sciences Ltd. logo
    WVE

    Wave Life Sciences Ltd.

    Dec 8, 2025
    Exercise
    Direct
    42K shares at avg. $5.97$251K
  • Wave Life Sciences Ltd. logo
    WVE

    Wave Life Sciences Ltd.

    Dec 8, 2025
    Sale
    Direct
    42K shares at avg. $15.00$630K
  • Wave Life Sciences Ltd. logo
    WVE

    Wave Life Sciences Ltd.

    Nov 13, 2025
    Sale
    Direct
    16.1K shares at avg. $6.79$109K
  • Wave Life Sciences Ltd. logo
    WVE

    Wave Life Sciences Ltd.

    Aug 11, 2025
    Award
    Direct
    12.7K shares-
  • Adaptimmune Therapeutics PLC logo
    ADAP

    Adaptimmune Therapeutics PLC

    Feb 20, 2025
    Award

    Option to purchase Ordinary Shares

    Direct
    3.4M shares-
  • Adaptimmune Therapeutics PLC logo
    ADAP

    Adaptimmune Therapeutics PLC

    Feb 20, 2025
    Award

    Option to purchase Ordinary Shares

    Direct
    5.1M shares-
  • Adaptimmune Therapeutics PLC logo
    ADAP

    Adaptimmune Therapeutics PLC

    Jan 17, 2025
    Sale
    Direct
    30.6K shares at avg. $0.58$18K
  • Adaptimmune Therapeutics PLC logo
    ADAP

    Adaptimmune Therapeutics PLC

    Jan 15, 2025
    Sale
    Direct
    29.1K shares at avg. $0.57$17K

1-10 of 12